Company
Sofgen Pharma S.A. (PROCF)
Standardized SEC financial data for Sofgen Pharma S.A. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001863362 · OTC · Pharmaceutical Preparations.
Gross margin
51.2%
Net margin
-18.3%
Revenue growth (YoY)
6221.6%
Return on equity
133.6%
Ratios for fiscal year 2024, standardized from SEC filings.
Income statement
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Revenue | $324.8M | $331.5M | $403.7M | $403.2M | $423.7M | $373.8M |
| Cost of revenue |
Balance sheet
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Goodwill | $7.0M | $6.9M | $6.8M | $5.8M | $0 | — |
| Total assets |
Get PROCF data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/PROCF/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/PROCF/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"